Rosavin

Rosavin at a Glance

Rosavin is a cinnamyl-alcohol diglycoside (C₂₀H₂₈O₁₀) — a molecule of cinnamyl alcohol carrying a glucose and an arabinose sugar. Its importance is less about what it does in the body than about what its presence signifies: rosavin, together with its siblings rosarin and rosin, is essentially unique to Rhodiola rosea, so it is the marker used to authenticate genuine roseroot against cheaper Rhodiola species that contain salidroside but little rosavin ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}.

Commercial Rhodiola extracts are standardised to a familiar ratio — roughly 3% “rosavins” and 1% salidroside — and rosavin is the most abundant of the three cinnamyl glycosides in that 3% ^{2Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}. This makes rosavin the headline number on nearly every Rhodiola label, even though most of the mechanistic adaptogenic work has centred on salidroside.

The purified molecule does have a genuine pharmacology, but it is entirely preclinical: rodent and cell studies report anti-osteoporotic, analgesic (via serotonin 5-HT₁A), anti-inflammatory and lipid-modulating effects ^{6,7,8Reference 6Wang Y et al. · 2025AnimalRosavin derived from Rhodiola alleviates colitis in mice through modulation of Th17 differentiationView study →Reference 7Li D et al. · 2021AnimalLi D, Park S, Lee K, Jang DS, Kim SK (2021). 5-HT1A receptors mediate the analgesic effect of rosavin in a mouse model of oxaliplatin-induced peripheral neuropathic pain. Korean Journal of Physiology & Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34448466/View study →Reference 8Zhang W et al. · 2021In vitroRosavin suppresses osteoclastogenesis in vivo and in vitro by blocking the NF-κB and MAPK signaling pathwaysView study →}. The honest headline is that the strong human evidence — anti-fatigue, mood, endurance — belongs to the standardised extract, not to isolated rosavin, and the isolate’s very low oral bioavailability (~2.5% in rats) is a real barrier to reading its in-vitro potency as an oral effect ^{5Reference 5Zhang M et al. · 2019AnimalPharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administrationView study →}.

The Rosavins & Rhodiola Standardisation

The single most important fact about rosavin is a quality-control one. Rhodiola rosea is an expensive, wild-harvested adaptogen, and it is routinely adulterated or substituted with cheaper relatives — R. crenulata, R. kirilowii, R. quadrifida and others. Almost all Rhodiola species share the phenylethanoid marker salidroside, so salidroside content alone cannot tell you which species is in the bottle ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →}.

The “rosavins” solve that. This group of three cinnamyl-alcohol glycosides — rosavin, rosarin and rosin — is largely confined to R. rosea, so their presence, and specifically the classic ~3:1 rosavins-to-salidroside ratio, is what authenticates true roseroot ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}. When HPLC of the marker compounds was first standardised for the genus, the rosavins were the discriminating peaks ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →}.

That is why commercial extracts are sold to a two-number specification — typically ~3% total rosavins and ~1% salidroside — mirroring the ratio found in the root ^{2Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}. Rosavin is the largest single contributor to the 3% figure, with rosarin and rosin making up the remainder. Two practical consequences follow:

• A product that lists salidroside but no rosavin may not be R. rosea at all.
• The “3% rosavins” on a label is a sum, not a rosavin-alone assay — rosavin, rosarin and rosin are counted together.

This authentication role, not any proven drug effect of the pure compound, is rosavin’s established significance.

Rosavin vs. Salidroside

Rhodiola’s activity is conventionally pinned on two marker groups, and it is worth keeping their jobs separate:

• Rosavin (and the rosavins) — the marker of authenticity. Cinnamyl-alcohol glycosides, essentially unique to R. rosea; they tell you the species is genuine. Their own isolated pharmacology is real but preclinical ^{3,4Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →Reference 4Aktar A et al. · 2024ReviewTherapeutic promises of bioactive rosavin: a comprehensive review with mechanistic insightView study →}.
• Salidroside — the more-studied active. A phenylethanoid glycoside (aglycone tyrosol) shared across the genus; most of the mechanistic adaptogenic, MAO-inhibiting, Nrf2-antioxidant and neuro/cardioprotective work is salidroside’s, and a human RCT has tested pure biosynthetic salidroside directly ^{2Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}.

The two are not interchangeable, and the “rosavin = active ingredient” shorthand on marketing copy overstates the isolate. In an electrophysiological screen of commercial extracts, both salidroside and rosavin enhanced hippocampal long-term potentiation, but extract efficacy did not track marker content in a simple way — a reminder that the standardised matrix, not a single number, is what was studied in people ^{12Reference 12Dimpfel W et al. · 2018Assessing the quality and potential efficacy of commercial extracts of Rhodiola rosea L. by analyzing the salidroside and rosavin content and the electrophysiological activity in hippocampal long-term potentiation, a synaptic model of memoryView study →}.

What It's Used For

Rosavin’s isolated pharmacology is a preclinical story — rodent models and cell work — layered on top of the whole-extract human evidence it is usually credited with.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is preclinical isolate or plant-extract work; there are no controlled human trials of purified rosavin, so scores stay modest by design. Read the per-row basis.

01Anti-osteoporotic / boneShaky38%Isolate: osteoclastogenesis ↓ (NF-κB/MAPK) in OVX mice + BMP-2/osteoblast in vitro ^{8,9,10Reference 8Zhang W et al. · 2021In vitroRosavin suppresses osteoclastogenesis in vivo and in vitro by blocking the NF-κB and MAPK signaling pathwaysView study →Reference 9Wojdasiewicz P et al. · 2025In vitroThe effect of rosavin, a characteristic compound of Rhodiola rosea, on BMP-2 induction and osteoblast proliferation in vitroView study →Reference 10Wojdasiewicz P et al. · 2024The role of rosavin in the pathophysiology of bone metabolismView study →}

02Analgesic / neuropathic painShaky34%Isolate: 5-HT₁A-dependent anti-allodynia in oxaliplatin neuropathy, mouse ^{7Reference 7Li D et al. · 2021AnimalLi D, Park S, Lee K, Jang DS, Kim SK (2021). 5-HT1A receptors mediate the analgesic effect of rosavin in a mouse model of oxaliplatin-induced peripheral neuropathic pain. Korean Journal of Physiology & Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34448466/View study →}

03Anti-inflammatory / colitisShaky30%Isolate: Th17/RORγt suppression in mouse colitis ^{6Reference 6Wang Y et al. · 2025AnimalRosavin derived from Rhodiola alleviates colitis in mice through modulation of Th17 differentiationView study →}

04Metabolic / lipid-loweringShaky26%Extract (3% rosavins/1% salidroside) anti-adipogenic in human visceral adipocytes ^{11Reference 11Pomari E et al. · 2015Effects of two different Rhodiola rosea extracts on primary human visceral adipocytesView study →}

05AntioxidantShaky22%In-vitro radical scavenging; review-level, as a constituent ^{3,4Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →Reference 4Aktar A et al. · 2024ReviewTherapeutic promises of bioactive rosavin: a comprehensive review with mechanistic insightView study →}

Mechanisms

The load-bearing point is scope: these are isolated-molecule or standardised-extract mechanisms in rodents and cells. None has been demonstrated for oral rosavin in humans, and the whole-plant human record is the extract’s, not the marker’s.

Pharmacokinetics

Rosavin’s pharmacokinetics are the section’s most useful reality check. In a validated UPLC-MS/MS study in rats, oral (gavage) rosavin showed an absolute oral bioavailability of only ~2.5% — attributed to hydrolysis of the glycoside in the acidic gut and first-pass metabolism ^{5Reference 5Zhang M et al. · 2019AnimalPharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administrationView study →}. In other words, most of an oral dose does not reach the circulation as intact rosavin; it is likely cleaved to cinnamyl-alcohol-derived fragments and sugars in the digestive tract. That single figure reframes the in-vitro potency in the sections above: concentrations that act on osteoclasts or adipocytes in a dish (tens to hundreds of µM) are unlikely to be achieved systemically from an oral standardised extract in which rosavin is only ~3% ^{5,9Reference 5Zhang M et al. · 2019AnimalPharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administrationView study →Reference 9Wojdasiewicz P et al. · 2025In vitroThe effect of rosavin, a characteristic compound of Rhodiola rosea, on BMP-2 induction and osteoblast proliferation in vitroView study →}. Human ADME for the isolate — Cmax, half-life, oral bioavailability — is not established; the PK data are rodent.

Clinical Trials

There are no controlled clinical trials of isolated rosavin. The human evidence attached to rosavin is entirely whole-extract Rhodiola rosea research (fatigue, mood, endurance), in which rosavin is present as the ~3% standardisation marker rather than the tested agent — those trials live on the Rhodiola herb page.

Last checked: July 2026.

Isolate vs. Plant Studies

Rosavin sits on the awkward side of the isolate-vs-plant divide. The mechanistic isolate work is real — the osteoclastogenesis, 5-HT₁A analgesia and Th17-colitis studies each tested purified rosavin (or rosavin “derived from Rhodiola”) in rodents and cells ^{6,7,8Reference 6Wang Y et al. · 2025AnimalRosavin derived from Rhodiola alleviates colitis in mice through modulation of Th17 differentiationView study →Reference 7Li D et al. · 2021AnimalLi D, Park S, Lee K, Jang DS, Kim SK (2021). 5-HT1A receptors mediate the analgesic effect of rosavin in a mouse model of oxaliplatin-induced peripheral neuropathic pain. Korean Journal of Physiology & Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34448466/View study →Reference 8Zhang W et al. · 2021In vitroRosavin suppresses osteoclastogenesis in vivo and in vitro by blocking the NF-κB and MAPK signaling pathwaysView study →}. But the human efficacy evidence is not rosavin’s — it belongs to the standardised extract studied for fatigue, mood and endurance, where rosavin is the ~3% authentication marker, not the isolated active ^{2,12Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →Reference 12Dimpfel W et al. · 2018Assessing the quality and potential efficacy of commercial extracts of Rhodiola rosea L. by analyzing the salidroside and rosavin content and the electrophysiological activity in hippocampal long-term potentiation, a synaptic model of memoryView study →}. Worse for a clean isolate story, much of the plant’s mechanistic “active” credit goes to salidroside, which has itself been tested as a pure compound in a human exercise RCT.

So the correct framing is: strong analytical identity + a genuine but preclinical isolate pharmacology + human data that are the extract’s, not the molecule’s. The commercial-extract screen makes the point directly — both rosavin and salidroside were active on hippocampal LTP, yet efficacy did not reduce to any single marker’s concentration ^{12Reference 12Dimpfel W et al. · 2018Assessing the quality and potential efficacy of commercial extracts of Rhodiola rosea L. by analyzing the salidroside and rosavin content and the electrophysiological activity in hippocampal long-term potentiation, a synaptic model of memoryView study →}.

Prevalence in Nature

Rosavin is, for practical purposes, a Rhodiola rosea compound. Among the medicinally used Rhodiola, the cinnamyl-alcohol glycosides (rosavin, rosarin, rosin) are largely confined to R. rosea, which is exactly why they authenticate the species against relatives such as R. crenulata, R. kirilowii and R. quadrifida that carry salidroside but little rosavin ^{1,2Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}. It accumulates in the roots and rhizomes, the medicinal part.

The one durable concentration figure is the standardisation target: commercial R. rosea extracts are set to ~3% total rosavins (rosavin + rosarin + rosin) alongside ~1% salidroside, echoing the ~3:1 ratio of the root ^{2Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}. Rosavin is the most abundant of the three, but published assays usually report the sum (“rosavins”) rather than rosavin alone, so a clean rosavin-only % dry-weight figure for raw root is not well pinned down (see the gaps tracker). Related species can be induced to make rosavins — hairy-root and cell cultures of R. kirilowii fed cinnamyl alcohol biotransform it into rosavin-group glycosides — but that is a biotechnology result, not natural abundance ^{13Reference 13Grech-Baran M et al. · 2014Biotransformation of cinnamyl alcohol to rosavins by non-transformed wild type and hairy root cultures of Rhodiola kirilowiiView study →}.

Discovery & Synthesis

Rosavin was first isolated from Rhodiola rosea root by Soviet/Russian botanists and chemists, who named it for its faint rose-like aroma (the same trait that gives roseroot its common name) ^{3Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}. It entered the Western literature chiefly through the marker-compound HPLC work that standardised Rhodiola authentication, where rosavin and its siblings were established as the species-discriminating peaks ^{1Reference 1Ganzera M et al. · 2001Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLCView study →}.

Manufacture today is overwhelmingly by extraction from cultivated or wild R. rosea root — the whole standardised extract, not purified rosavin, is the commercial product. A total synthesis has been reported: a 2021 route from cinnamyl alcohol and peracetylated α-D-bromoglucose reached rosavin in seven steps at ~16% overall yield, described as low-cost and mild ^{3Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}. Biotechnological routes are also under study — precursor-fed Rhodiola hairy-root and cell cultures convert exogenous cinnamyl alcohol into rosavins, a potential sustainable alternative to wild harvest of a pressured species ^{13Reference 13Grech-Baran M et al. · 2014Biotransformation of cinnamyl alcohol to rosavins by non-transformed wild type and hairy root cultures of Rhodiola kirilowiiView study →}. Biosynthetically, rosavin is a phenylpropanoid: phenylalanine → cinnamoyl-CoA → cinnamaldehyde → cinnamyl alcohol, which is glucosylated to rosin and then decorated with an arabinose to give rosavin ^{3Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →}.

Patents: not yet researched.

Toxicity & Safety

Rosavin carries a low toxicity flag. It is a dietary-scale plant glycoside whose principal human exposure is as a minor (~3%) fraction of a standardised Rhodiola rosea extract that is itself well tolerated in short-term trials. No isolate-specific human toxicology exists, so the cautions below are inherited from the whole extract and tempered by the compound’s very low oral bioavailability.

Safety at a Glance

✅ Low / no toxicity

• Low apparent toxicity. A cinnamyl-alcohol glycoside present at dietary scale in a well-tolerated adaptogen; no signal of isolate toxicity in the preclinical work ^{3,6,8Reference 3Wang S et al. · 2023Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea LView study →Reference 6Wang Y et al. · 2025AnimalRosavin derived from Rhodiola alleviates colitis in mice through modulation of Th17 differentiationView study →Reference 8Zhang W et al. · 2021In vitroRosavin suppresses osteoclastogenesis in vivo and in vitro by blocking the NF-κB and MAPK signaling pathwaysView study →}.
• Exposure ≠ potency. Oral bioavailability is only ~2.5% in rats (gut hydrolysis + first-pass), so the high in-vitro concentrations that drive effects are unlikely to be reached by an oral extract — read isolate potency with caution ^{5Reference 5Zhang M et al. · 2019AnimalPharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administrationView study →}.
• No human isolate safety data. Cautions are borrowed from whole Rhodiola — modest human CYP2C9 inhibition (relevant to narrow-therapeutic-index drugs like warfarin/phenytoin) and stimulant-like activation — not measured for purified rosavin.
• Pregnancy & lactation not established. This is decided on the Rhodiola herb or the product page where intake is chosen, not on this molecule page; the EMA does not recommend Rhodiola in pregnancy on absence-of-data grounds.

Dosage

There is no established or recommended human dose for isolated rosavin. Its real-world “dose” is structural, not therapeutic — it is the ~3% rosavins figure on a standardised Rhodiola rosea label, taken as part of the whole extract (commonly 144–680 mg of extract per day in the human trials, which works out to roughly 4–20 mg of total rosavins) rather than as a purified compound ^{2Reference 2Panossian A et al. · 2010ReviewRosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — reviewView study →}.

The isolate figures are animal research doses, not human recommendations, and the very low oral bioavailability makes a naive human back-calculation meaningless ^{5Reference 5Zhang M et al. · 2019AnimalPharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administrationView study →}. These are research and standardisation figures, not a personal recommendation.

References

1. Ganzera M, Yayla Y, Khan IA (2001). Analysis of the marker compounds of Rhodiola rosea L. (golden root) by reversed phase HPLC. Chemical and Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/11310675/
2. Panossian A, Wikman G, Sarris J (2010). Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy — review. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/20378318/
3. Wang S, Feng Y, Zheng L, He P, Tan J, Cai J, Wu M, Ye X (2023). Rosavin: research advances in extraction and synthesis, pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea L. Molecules. https://pubmed.ncbi.nlm.nih.gov/37959831/
4. Aktar A, Bhuia S, Chowdhury R, Hasan R, Rakib AI, Al Hasan S, Sonia FA, Islam MT (2024). Therapeutic promises of bioactive rosavin: a comprehensive review with mechanistic insight. Chemistry & Biodiversity. https://pubmed.ncbi.nlm.nih.gov/38752614/
5. Zhang M, Hu Z, Fang B, Bao X, Xiang Z, Wang H (2019). Pharmacokinetic study of rosavin in rat plasma with ultra performance LC-MS/MS after intravenous and gavage administration. Bioanalysis. https://pubmed.ncbi.nlm.nih.gov/31094215/
6. Wang Y, Jiang Y, Li M, Xiao Y, Zhao Q, Zeng J, et al. (2025). Rosavin derived from Rhodiola alleviates colitis in mice through modulation of Th17 differentiation. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/39647466/
7. Li D, Park S, Lee K, Jang DS, Kim SK (2021). 5-HT1A receptors mediate the analgesic effect of rosavin in a mouse model of oxaliplatin-induced peripheral neuropathic pain. Korean Journal of Physiology & Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34448466/
8. Zhang W, Zhang W, Huo L, Chai Y, Liu Z, Ren Z, Yu C (2021). Rosavin suppresses osteoclastogenesis in vivo and in vitro by blocking the NF-κB and MAPK signaling pathways. Annals of Translational Medicine. https://pubmed.ncbi.nlm.nih.gov/33842604/
9. Wojdasiewicz P, Wróbel E, Stolarczyk K, Stolarczyk EU, Mikulska A, Szukiewicz D (2025). The effect of rosavin, a characteristic compound of Rhodiola rosea, on BMP-2 induction and osteoblast proliferation in vitro. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/40649853/
10. Wojdasiewicz P, Turczyn P, Lach-Gruba A, Poniatowski ŁA, Purrahman D, Mahmoudian-Sani MR, Szukiewicz D (2024). The role of rosavin in the pathophysiology of bone metabolism. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/38396794/
11. Pomari E, Stefanon B, Colitti M (2015). Effects of two different Rhodiola rosea extracts on primary human visceral adipocytes. Molecules. https://pubmed.ncbi.nlm.nih.gov/25970041/
12. Dimpfel W, Schombert L, Panossian AG (2018). Assessing the quality and potential efficacy of commercial extracts of Rhodiola rosea L. by analyzing the salidroside and rosavin content and the electrophysiological activity in hippocampal long-term potentiation, a synaptic model of memory. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/29881348/
13. Grech-Baran M, Sykłowska-Baranek K, Krajewska-Patan A, Wyrwał A, Pietrosiuk A (2014). Biotransformation of cinnamyl alcohol to rosavins by non-transformed wild type and hairy root cultures of Rhodiola kirilowii. Biotechnology Letters. https://pubmed.ncbi.nlm.nih.gov/24190481/

View all 13 references▾